Strides Arcolab gets USFDA nod for new tablets

Strides Arcolab today said it has received approval from the United States Food & Drug Administration (USFDA) for Lamivudine and Zidovudine tablets to treat HIV infection.
Lamivudine and Zidovudine are generic version of Viiv's Combivir that belong to a group of antiviral medicines, also known as antiretrovirals and is used with other anti retroviral medicines to treat HIV infection in adults and children.
Lamivudine and Zidovudine 150 mg/300 mg tablets reduce the amount of HIV in body and keeps it at a low level.
The product will be manufactured at the company's oral dosage facility at Bangalore and marketed by Strides in the US market. The product will be launched in the markets immediately, a company statement said here.

According to IMS data, the US market for Lamivudine and Zidovudine tablets is approximately USD 120 million.